Fauna Bio Raises $9M in Seed Funding finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR's .
Amplyx Pharmaceuticals acquired by Pfizer
DJ Amplyx Pharmaceuticals acquired by Pfizer
Arix Bioscience PLC (ARIX)
Amplyx Pharmaceuticals acquired by Pfizer
28-Apr-2021 / 12:02 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Amplyx Pharmaceuticals acquired by Pfizer
LONDON, 28 April 2021: Arix Bioscience plc, ( Arix , LSE: ARIX), a global venture capital company focused on investing
in and building breakthrough biotech companies, notes that its portfolio company Amplyx Pharmaceuticals ( Amplyx ), a
privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that
affect people with compromised immune systems, has been acquired by Pfizer Inc.
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix
Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
. | April 28, 2021
Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types
i. Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy. As there are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of impo